Article

Novel Synthesis and Antitumor Evaluation of Polyfunctionally Substituted Heterocyclic Compounds Derived from 2-Cyano-*N*-(3-cyano-4,5,6,7-tetrahydrobenzo[*b*]thiophen-2-yl)-acetamide

Hoda Z. Shams [1], Rafat M. Mohareb [2,3,]*, Maher H. Helal [1] and Amira E. Mahmoud [1]

[1] Department of Chemistry, Faculty of Science, Helwan University, Ain Helwan, Cairo, Egypt
[2] Department of Organic Chemistry, Faculty of Pharmacy, October University for Modern Sciences and Arts, October City, Egypt
[3] Department of Chemistry, Faculty of Science, Cairo University, Giza, Egypt

* Author to whom correspondence should be addressed; E-Mail: raafat_mohareb@yahoo.com; Tel.: +202-37626269 or +202-35676570.

Abstract: The reaction of 2-amino-3-cyano-4,5,6,7-tetrahydrobenzo[*b*]thiophene with ethyl cyanoacetate gave 2-cyano-*N*-(3-cyano-4,5,6,7-tetrahydrobenzo[*b*]thiophen-2-yl)-acetamide. The latter was used to synthesize different heterocyclic derivatives comprising thiophene, thiazole, pyrazole, pyridine, pyrimidine, and coumarin rings. The mechanistic and synthetic pathways depended on regioselective attack and/or cyclization by the cyanoacetamido moiety in the key precursor on various chemical reagents. The competition of the reaction pathways including dipolar cyclization, dinucleophilic-bielectrophilic attack, β-attack, Gewald-type attack, and condensation reactions led to the diversity of the synthesized products. The antitumor activities of the synthesized products were studied and evaluated. Most of the compounds revealed high inhibitory effects when screened *in vitro* for their antiproliferative activity. Three human cancer cell lines, namely, breast adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460) and CNS cancer (SF-268) were used in the screening tests. The simplicity of the synthetic procedures which mainly involved one-pot reactions under mild reaction conditions, the convenience of yield production and the diversity of the reactive sites in the produced systems play a valuable role for further heterocyclic transformations and further biological investigations.

Keywords: 4,5,6,7-tetrahydrobenzo[*b*]thiophene; thiazole; pyrazole; pyridine; antitumor

1. Introduction

Benzothiophene systems and their substituted derivatives have attracted a great deal of interest over the years. Their aromatic character contributes to their reactivity, stability and chemical and electronic properties. A vast number of heterocyclic derivatives observed in natural products have been reported [1-2]. On the other side, they find increasing application as superconductors [3-4], optoelectronics [5-6], light emission diodes LEDs, and non-linear optical (NLO) chromophores [7,8]. Besides, their pharmacological profiles as antimicrobial [9-10], antifungal [11], antiinflammatory [12], antiproliferative [13-15] and antioxidant [16] agents have led to an enduring interest in the development of various methods for their synthesis. The most efficient protocols for carrying out the synthesis of such thiophene derivatives are the Gewald method [17-18], intramolecular cyclization via both nucleophilic displacement [14,19] and thio-Claisen rearrangement [20], and dehydrophoto-cyclization [21-22]. Of particular interest are methods that utilize new classes of precursors. Among the many synthetic methods available are C-C bond formation using Montmorillonite K-10 as Friedel Crafts catalyst [23]. C-C and C-N bond formation via transition metal catalyzed processes involving palladium-mediated cross-coupling cyclizations (e.g., Suzuki, Sonogashira and Buchwald-Hartwig cross coupling), also feature heavily [24-28]. Within the scope of these diverse synthetic methods and the utility of thiophene-based systems and in continuation to our interest in the design of bioactive heterocycles [29-31], we focused our efforts to developing novel highly substituted and polyfunctional heterocyclic compounds based on the key precursor 2-cyano-*N*-(3-cyano-4,5,6,7-tetrahydrobenzo[*b*]-thiophen-2-yl)-acetamide (**2**) and evaluating their antitumor activities.

2. Results and Discussion

2.1. Chemistry

The synthetic strategies adopted to obtain the newly synthesized compounds **3-17** depended on the regioselective attack on the cyanoacetamido moiety of the key precursor **2** by different reagents, which, in one or two steps added a highly functionalized substituent or heterocyclic ring to the molecule. The mechanistic pathways for our protocol are outlined in Schemes 1-9. CHNS microanalytical data, IR, ^{1}H-NMR and MS spectral data are indicated in the Experimental section.

The reaction of 2-amino-3-cyano-4,5,6,7-tetrahydrobenzo[*b*]thiophene (**1**) [32] with ethyl cyano-acetate gave 2-cyano-*N*-(3-cyano-4,5,6,7-tetrahydrobenzo[*b*]thiophen-2-yl)-acetamide **2** (Scheme 1). The IR spectrum of **2** revealed two CN stretching bands at 2,262 and 2,196 cm^{-1}, and a characteristic C=O stretching at 1,696 cm^{-1}. Moreover, the ^{1}H-NMR spectrum exhibited a multiplet due to four CH_2 groups at δ 1.70-2.60, a singlet at δ 4.11 for the acetamido CH_2 and a singlet at δ 6.94 ppm for the amidic NH. GC-MS analysis of compound **2** exhibited a [M$^+$] ion (*m/z* 245), confirming the molecular weight of this compound. The peak at *m/z* 178 indicated the fragmentation of [COCH$_2$CN]$^+$ (*m/z* 68) from [M$^+$ + 1]. The base peak observed at *m/z* 150 represented the fragmentation of [CNHCOCH$_2$CN]$^+$ (*m/z* 95) from the [M$^+$] ion. Compound **2** underwent ready cyclization when heated in 1,4-dioxane containing triethylamine to give the tetrahydrobenzo[4,5]thieno[2,3-*b*]pyridine derivative **3** (Scheme 1).

Scheme 1. Synthesis of the precursor **2** and its cyclized product **3**.

The absence of one of the two CN functions (IR) and of δ singlet CH_2 (^{1}H NMR) observed in compound **2** as well as the appearance of a NH_2 singlet at δ 3.61 ppm (^{1}H-NMR) confirmed the fused structure **3**. It is noteworthy that the IR spectrum of compound **3** showed a C=O stretching band at 1,621 cm^{-1} and its ^{1}H-NMR showed a D_2O exchangeable singlet at δ 6.97 ppm corresponding to the NH group, confirming that **3** exists in both keto and enol forms. Compound **3** revealed a [M$^+$] (*m/z* 245) which is also the base peak.

The reactivity of compound **2** towards various chemical reagents was investigated with the aim to producing thiophene systems with potential biological activities. Thus, the reaction of **2** with salicylaldehyde gave the coumarin derivative **4**. On the other hand, the reaction of **2** with either benzaldehyde or acetophenone gave the benzylidene derivatives **5** and **6**, respectively (Scheme 2).

Scheme 2. Synthesis of the coumarin derivative **4** and benzal derivatives **5** and **6**.

All collected data for compounds **4-6** were consistent with the proposed structures. Thus, the observation of δ-^{1}H benzylidine C=CH at 8.56 ppm in the ^{1}H-NMR spectrum of **5** and a coumarin C4-H proton at δ 6.94 ppm in the ^{1}H-NMR spectrum of **4,** as well as the appearance of a high frequency C=O stretching at 1,715 cm^{-1} cited for the coumarin oxo function besides the absence of the cyanoacetamido CN observed in the starting material **2**, in the IR spectrum of **4** proved the expected structures. Compounds **5** and **4** revealed molecular ion peaks [M$^+$] at *m/z* 333 and [M$^+$ − 1] (*m/z* 349), corresponding to the molecular formulae $C_{19}H_{15}N_3OS$ and $C_{19}H_{14}N_2O_3S$, respectively. A base peak at

m/z 266 due to splitting of the fragment ion [C(=O)-C-CN]⁺ (*m/z* 66) from the [M⁺ − 1] ion of **5**, and a base peak at *m/z* 172 which resulted from the fragmentation of [3-CN-4,5,6,7-tetrahydrobenzo [*b*]thiophene-2-NH]⁺ (*m/z* 177) from the [M⁺ − 1] ion of **4** were observed in their respective mass spectra.

When compound **2** was reacted with acetophenone in the presence of ammonium acetate in an oil bath at 140 °C the Knoevenagel condensation product **6** was obtained (Scheme 2). The structure of compound **6** was based on analytical and spectral data (see Experimental section). Moreover, the GC-MS spectrum of compound **6** revealed a molecular ion peak [M⁺ − 1] at *m/z* 346, a base peak at *m/z* 150, resulting from the fragmentation of [CNHC(=O)C(CN)=C(CH₃Ph)]⁺ (*m/z* 197) from the [M⁺] ion, and a fragment ion peak at *m/z* 178 due to the fragmentation of [C(=O)C(CN)=C(CH₃Ph)]⁺ (*m/z* 170) from the [M⁺ + 1] ion peak.

When compound **4** reacted with either hydrazine hydrate or phenyl hydrazine, the respective pyrazole systems **7a**,**b** were obtained as the major products (Scheme 3). The reaction involves β-attack on the C(=O)C=C moiety in **4** with subsequent 1,5-intramolecular dipolar cyclization and concomitant aromatization.

Scheme 3. Synthesis of pyrazole systems **7a,b**.

Minor products **8a,b** were also obtained through the first condensation with the amide C=O followed by cyclization. Microanalysis and spectral data of **7a**,**b** were fully consistent with the proposed structures. The mass spectrum of the pyrazole system **7b** exhibited a molecular ion peak [M$^+$] (*m/z* 439) corresponding to molecular formula $C_{25}H_{21}N_5OS$.

On the other hand, treatment of the benzylidene derivative **4** with methylene carbonitrile reagents (XCH$_2$CN; X = CN, X = CO$_2$Et) afforded the respective pyridone derivatives **9a,b** (Scheme 4). The reaction took place via β-attack on the benzylidene moiety in **4** followed by 1,6-intramolecular dipolar cyclization with concomitant aromatization. The IR spectrum of **9a** revealed the presence of three CN stretching bands at υ 2,253, 2,223 and 2,209 cm^{-1}. Moreover, the ^{1}H-NMR spectra of **9a** and **9b** showed the presence of one singlet for each at δ 3.61 and δ 3.41 ppm, respectively, due to the presence of the NH$_2$ group. Compound **9b** showed a triplet at δ 1.21 for the ester CH$_3$ group and a quartet at δ 4.30 corresponding to the ester CH$_2$ group. Moreover, in the mass spectrum of **9a** the existing [M$^+$] ion (*m/z* 397) corresponding to the formula $C_{22}H_{15}N_5OS$ and representing the base peak was observed, whereas the mass spectrum of **9b** exhibited a molecular ion peak [M$^+$] at *m/z* = 444 confirming its molecular formula $C_{24}H_{20}N_4O_3S$.

Further confirmation of the reaction products **9a,b** was achieved through an alternative synthetic route involving treatment of the starting compound **2** with benzylidene carbonitrile reagents (PhCH=C(CN)X; X = CN; X = CO$_2$Et) to afford the same pyridone derivatives **9a,b** (verified by IR fingerprint, m.p. and mixed m.p.) with better yields (80%, 86%) than in their formation by the reaction of compound **4** and either malononitrile (75% yield) or ethyl cyanoacetate (73% yield) (Scheme 4).

Scheme 4. Synthesis of pyridone derivatives **9a,b**.

By subjecting the starting material **2** to reaction with active methylene reagents (X CH$_2$Y; X = Y = CN; X = CN, Y = CO$_2$Et; X = Y = COCH$_3$ or X = COCH$_3$, Y = CO$_2$Et) the respective 2-pyridone derivatives **10a-d** were obtained (Scheme 5).

Scheme 5. Synthesis of 2-pyridone derivatives **10a-d**.

a, X= Y= CN
b, X= CN, Y= CO$_2$Et
c, X= Y= COMe
d, X= COMe, Y= CO$_2$Et

Cyclization : 1,3-dinucleophile with 1,3-bielectrophile

10a, X= Y= NH$_2$
  b, X= NH$_2$, Y= OH
  c, X= Y= Me
  d, X= Me, Y= OH

All data for compounds **10a-d** were consistent with the proposed structures. Thus, the absence of the δ-^{1}H CH$_2$ cited for the acetamido methylene protons observed with **2** at δ 4.11 ppm and the appearance of the pyridine C5-H protons at δ 7.89, 6.92, 6.51 and 6.88 ppm in the respective ^{1}H-NMR spectra of **10a-d** confirmed the proposed structures. Moreover, the CH$_3$ proton singlets were recorded at δ 2.11 and 2.36 ppm with compound **10c** and at δ 2.55 ppm with **10d**, whereas the δ-^{1}H signals for OH were integrated at 11.89 and 12.10 ppm in the respective ^{1}H-NMR spectra of compounds **10b,d**. The mass spectra of **10a,b** exhibited a common peak at *m/z* 311 which corresponded to their [M$^+$] and [M$^+$ − 1] ions, respectively. Another common peak was also observed at *m/z* 296 due to splitting of NH$_2$ from their respective [M$^+$ + 1] and [M$^+$] molecular ions. The peak observed for **10a** at *m/z* 282 is due to the fragmentation of two NH$_2$ from [M$^+$ + 3], while that observed for **10b** at *m/z* 285 corresponded to the loss of CN group from its [M$^+$ − 1]. The mass spectrum of **10b** exhibited two fragment ion peaks at *m/z* 219 and 164 due to fragmentation of [C(=O)-C(CN)=C-(NH$_2$)]$^+$ from [M$^+$ + 1] and of functionalized pyridone (C$_6$H$_5$N$_3$O$_2$) from [M$^+$ + 3]. The mass spectrum of **10c** displayed a [M$^+$] base peak at *m/z* 309 corresponding to the molecular formula C$_{17}$H$_{15}$N$_3$OS. Compound **10c** revealed two main fragment ions at *m/z* 162 and *m/z* 147 due to splitting of 3-CN-4,5,6,7-tetrahydrobenzo[*b*]-thiophene [C$_9$H$_8$NS]$^+$ and the functionalized pyridone C$_8$H$_7$N$_2$O fragments, respectively.

The peak observed at *m/z* 131 is due to the fragmentation of 2-amino-3-cyano-4,5,6,7-tetrahydrobenzo[*b*]thiophenyl cation [C$_9$H$_{10}$N$_2$S]$^+$ from the molecular ion peak [M$^+$] of **10c** whereas that observed at *m/z* 281 resulted from fragmentation of CN from [M$^+$ − 2]. On the other hand, compound **10d** exhibited [M$^+$ + 2] at *m/z* 313 indicating a molecular formula C$_{16}$H$_{13}$N$_3$O$_2$S, and a base peak *m/z* 219 due to fragmentation of [C(=O)-C(CN)=C(CH$_3$)]$^+$ (*m/z* 93) from its [M$^+$ + 1]. Two fragments observed at *m/z* 163 and *m/z* 150 resulted from splitting of 3-cyano-4,5,6,7-tetrahydrobenzo-[*b*]thiophenyl cation [C$_9$H$_9$NS]$^+$ and functionalized pyridone [C$_7$H$_6$N$_2$O$_2$]$^+$, respectively.

At the other extreme, when compound **2** reacted with elemental sulfur and either of the methylene carbonitrile reagents (X-CH$_2$-CN or X = CN; X = CO$_2$Et) it gave the thiophene derivatives **11a,b**, respectively. The reaction of compound **2** with phenyl isothiocyanate and elemental sulfur gave the thiazole-2-thione derivative **12**. Formation of **11a,b** took place through intermediate formation of A and B, while the formation of **12** occurred through intermediacy of A and C (Scheme 6).

Scheme 6. Synthesis of the highly functionalized thiophenes **11a,b** and thiazole **12**.

The ^{1}H-NMR spectrum of compound **11a** revealed the existence of two singlets at δ 3.34 and 3.38 ppm corresponding to two NH$_2$ groups, while compound **11b** showed two singlets at δ 3.31 and 3.35 ppm corresponding to the two NH$_2$ groups, a triplet at δ 1.12 for the ester CH$_3$ group and a quartet at δ 3.49 for the ester CH$_2$ group. GC-MS analysis of **11a,b** and **12** showed molecular ion peaks [M$^+$ + 3] *m/z* 346, [M$^+$ + 2] *m/z* 392 and [M$^+$] *m/z* 412. The main fragmentation of **11a,b** and **12** gave the most abundant peak recorded at *m/z* 150, which corresponded to the fragment ion [C$_8$H$_8$NS]$^+$ resulting from the fragmentation of [3,5-di-NH$_2$-4-CN-thiophene-2-CONHC]$^+$ (*m/z* 193), [3,5-di-NH$_2$-4-C(=O)OEt-thiophene-2-CONHC]$^+$ (*m/z* 240) and [4-NH$_2$-3-Ph-2-thione-2,3- dihydrothiazole-5-CONHC]$^+$ (*m/z* 262), respectively, from their corresponding molecular ions [M$^+$]. The peak observed at *m/z* 150 represented the base peak for **11a**. A base peak observed at *m/z* 362 in the mass spectrum of **11b**

indicated the fragmentation of [C-NH$_2$]$^+$ (*m/z* 28) from the [M$^+$] ion, whereas the base peak observed at *m/z* 93 in the mass spectrum of **12** corresponded to the cleavage of Ph-NH$_2$. A common peak observed at *m/z* 178 in the mass spectra of **11a,b** and **12** indicated the loss of 2-NH$_2$-3-CN-4,5,6,7-tetrahydrobenzo[*b*]-thiophene.

Next, we moved to the studying of the the reaction of compound **2** with phenyl isothiocyanate in 1,4-dioxane containing triethylamine. The reaction involved a nucleophilic attack by the amidic NH function in **2** on the C=S terminal of the isocyanate reagent to produce the acyclic intermediate **A**. The latter then underwent 1,6-dipolar cyclization to afford the 6-thioxo-2-pyrimidone derivative **13** as the major product (Scheme 7).

Scheme 7. Synthesis of 2-pyrimidone-6-thione **13**.

The data obtained from the IR, ^{1}H-NMR and MS spectra are in agreement with the proposed structure. Thus, the ^{1}H-NMR of compound **13** exhibited singlets at δ 6.92 and 3.83 ppm due to pyrimidine C3-H and NH$_2$, respectively. The mass spectrum of **13** revealed a [M$^+$ + 2] ion peak at *m/z* 382, a base peak at *m/z* 313 due to fragmentation of [C(=O)-CH=C-NH$_2$]$^+$ (*m/z* 69) from the [M$^+$ + 2] as well as a fragment ion at *m/z* 255 due to fragmentation of [C(=S)=N-C(=O)-C=C-NH$_2$]$^+$ (*m/z* 126) from [M$^+$ + 1].

On the other hand, we are involved in a comprehensive programme studying the reactivity of active methylene reagents towards phenyl isothiocyanate in basic dimethylformamide followed by heterocyclization with α-halocarbonyl compounds. These reactions lead to the formation of either thiophene or thiazole systems or both, depending on reaction conditions and the nature of the α-halo-carbonyl reagent [33]. Thus, subjecting the active methylene key precursor **2** to the aforementioned reaction using α-halocarbonyl reagents XCH$_2$C(=O)R (X = Cl, R = OEt; X = Br, R = Ph; X = Cl, R = CH$_3$) afforded the functionalized thiophene and thiazole derivatives **14a,b** and **15**, respectively (Scheme 8). The reaction took place through the intermediacy of the potassium sulphide salt **A**. The disappearance of δ-^{1}H CH$_2$ singlet observed in the precursor **2**, and the appearance of D$_2$O exchangeable NH$_2$ singlets at δ 4.37 and δ 4.80 ppm for compounds **14a** and **14b**, respectively, as well as the appearance of a δ-^{1}H singlet at 6.67 ppm assigned to a thiazole C$_5$-H proton in compound **15** are considered sufficient proof for the structures of **14a,b** and **15**. Moreover, The mass spectra of **14a,b**

and **15** displayed [M$^+$] ion peaks at *m/z* 466, 498 and 418, respectively, corresponding to their respective molecular formulae $C_{23}H_{22}N_4O_3S_2$, $C_{27}H_{22}N_4O_2S_2$ and $C_{22}H_{18}N_4OS_2$. The main fragmentation of the title compounds revealed three important common peaks: *m/z* 77 due to [phenyl]$^+$, *m/z* 178 due to 2-NH$_2$-3-CN-4,5,6,7-tetrahydrobenzo[*b*]thiophene, and *m/z* 150 to [C_8H_8NS]$^+$. Such *m/z* peaks resulted from the fragmentation of [3-NH$_2$-2-COOEt-5-NHPh-thiophene-4-CONH-C]$^+$ (*m/z* 316), [3-NH$_2$-2-COPh-5-NHPh-thiophene-4-CONH-C]$^+$ (*m/z* 348) and [4-CH$_3$-3-Ph-3H-thiazol-2-ylidine-C-(CN)-CONH-C]$^+$ (*m/z* 268) from their corresponding [M$^+$] ions. The peak observed at *m/z* 77 due to [phenyl]$^+$ represented the base peak for both compounds **14a,b**.

Scheme 8. Synthesis of thiophene derivatives **14a,b** and the thiazole **15**.

Compound **15** displayed a base peak at *m/z* 241 due to the loss of a 2-amino-3-cyano-4,5,6,7-tetra-0hydrobenzo[*b*]thiophenyl cation (*m/z* 178) from its [M$^+$ + 1] molecular ion. Other fragment ions were observed in the mass spectra of **14a,b** and **15** at their expected *m/z* values.

On the other hand, compound **2** reacted with benzenediazonium chloride to give the phenylhydrazo derivative **16**. The latter compound reacted with either malononitrile or ethyl cyanoacetate to give the 3-phenylazo-pyridone derivatives **17a** and **17b**, respectively (Scheme 9). The structural assignments of **16**, **17a,b** were based on analytical and spectral data. Thus, the ^{1}H-NMR spectrum of compound **16** revealed two singlets at δ 9.14 and 10.88 ppm (D$_2$O exchangeable) due to the two NH groups. Moreover, the mass spectrum of **16** showed a molecular ion peak at *m/z* 349 [M$^+$], and a base peak at *m/z* 178 which corresponded to the loss of [C(=O)-C(CN)=N-NHPh]$^+$ (*m/z* 172) from [M$^+$ + 1]. Fragment ions at *m/z* 149 due to fragmentation of [C-(NH)-C(=O)-C(CN)=N-NHPh]$^+$ (*m/z* 197) from [M$^+$ − 1], and the peak at *m/z* 167 resulting from fragment ion [NH-C(=O)-C(CN)=N-NHPh]$^+$ (*m/z* 187) from [M$^+$ + 5].

Scheme 9. Synthesis of 2-pyridone-3-phenylazo derivatives **17a,b**.

Common features of compounds **17a,b** are their strong carbonyl absorptions around 1,680 cm^{-1} in their IR spectra, in addition to the ester C=O peak at 1,739 cm^{-1}. Moreover, the ^{1}H-NMR spectra of **17a** and **17b** showed a singlet a δ ~ 3.10 (D$_2$O exchangeable) corresponding for the NH$_2$ protons. Compound **17b** showed a triplet at δ 1.20 for the ester CH$_3$ group and a quartet at δ 4.13 ppm for the ester CH$_2$ group. The mass spectra of **17a,b** displayed molecular ion peaks at *m/z* 415 and *m/z* 462 corresponding to their respective [M$^+$]. A base peak at *m/z* 178 due to fragmentation of [C(=O)-C(N=NPh)=C(NH$_2$)-C(CN)=C(NH$_2$)]$^+$ (*m/z* 239) from [M$^+$ + 2] was detected in the mass spectrum of **17a**, while compound **17b** displayed a base peak at *m/z* 133 which corresponds to [CN-C=C-NH-C(=O)-C=C-NH$_2$]$^+$. A common fragment ion *m/z* 349 was observed in both mass spectra of **17a** and **17b** due to fragmentation of [CN-C=C-NH$_2$]$^+$ (*m/z* 66) and of [CO$_2$Et-C=C-NH$_2$]$^+$ (*m/z* 113) from their respective [M$^+$]. The peak observed with **17a** at *m/z* 106 is attributed to splitting of the phenylhydrazono moiety [N-NHPh]$^+$.

2.2. Biology

2.2.1. *In vitro* evaluation of antiproliferative activity of the synthesized compounds

The tumor cell growth inhibition activities of the newly synthesized thiophene systems (22 compounds in total) were assessed *in vitro* [34] on three human tumor cell lines, namely, MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer), and SF-268 (CNS cancer) after a continuous exposure of 48 h. The results were compared to the antiproliferative effects of the reference control doxorubicin [35]. All the compounds were dissolved in DMSO at 1 mg/mL immediately before use and diluted just before addition to the cell culture.

The data (Table 1) represents means ± SEM of three independent experiments performed in duplicate. The results indicated that most compounds demonstrated substantial growth inhibitory effects against the human tumor cells at the concentrations tested. The antiproliferative activity of the test compounds against each of the title tumor cell lines may be arranged in a descending order due to measured concentration required to inhibit tumor cell proliferation by 50% (GI$_{50}$ μ/M).

Table 1. Antiproliferative activity GI_{50} (μM) of the synthesized compounds.

Compound	GI_{50} (μM) [a]		
	MCF-7	**NCI-H460**	**SF-268**
2	30.0 ± 0.6	19.3 ± 1.4	26.3 ± 1.5
3	44.6 ± 12.6	32.6 ± 8.6	60.4 ± 14.8
4	10.8 ± 0.6	16.5 ± 0.8	16.7 ± 1.6
5	75.7 ± 17.5	40.2 ± 12.8	52.0 ± 9.0
6	37.4 ± 10.2	22.1 ± 0.8	14.9 ± 6.8
7a	2.5 ± 0.5	10.4 ± 0.6	8.0 ± 0.4
7b	74.9 ± 0.9	40.6 ± 1.8	58.8 ± 0.8
9a	38.0 ± 1.8	40.0 ± 0.8	22.5 ± 1.1
9b	20.0 ± 0.2	30.6 ± 1.4	38.4 ± 0.6
10a	16.7 ± 1.6	10.8 ± 0.6	16.5 ± 0.8
10b	50.1 ± 0.7	23.2 ± 4.8	18.4 ± 1.8
10c	39.0 ± 1.8	46.0 ± 0.8	22.5 ± 1.1
10d	22.0 ± 0.2	30.6 ± 1.4	38.4 ± 0.6
11a	66.6 ± 12.2	12.0 ± 6.2	24.8 ± 3.2
11b	22.0 ± 0.4	26.3 ± 0.8	39.0 ± 0.8
12	10.9 ± 0.2	146.1 ± 0.6	22.3 ± 0.5
13	42.6 ± 12.2	32.6 ± 8.6	64.4 ± 14.8
14a	20.0 ± 0.2	32.6 ± 1.4	36.4 ± 0.6
14b	11.8 ± 0.6	14.5 ± 0.8	16.7 ± 1.6
15	36.4 ± 10.2	20.1 ± 0.8	18.9 ± 6.8
17a	2.0 ± 0.4	8.3 ± 0.8	4.0 ± 0.8
17b	68.6 ± 12.2	12.0 ± 6.2	24.8 ± 3.2
*Doxorubicin	0.0428 ± 0.0082	0.0940 ± 0.0087	0.0940 ± 0.0070

[a] Drug concentration required to inhibit tumor cell proliferation by 50% after continuous exposure of 48 h; data are expressed as means ±SEM of three independent experiments performed in duplicates; *Doxorubicin was used as positive control.

The sequence "tumor cell ", [test compound number] and (GI_{50} μ/M) followed the sequence:

"MCF-7" [Doxorubicin] (0.0428 ± 0.0082), **[17a]** (2.0 ± 0.4), **[7a]** (2.5 ± 0.5), **[4]** (10.8 ± 0.6), **[12]** (10.9 ± 0.2), **[14b]** (11.8 ± 0.6), **[10a]** (16.7 ± 1.6), **[9b, 14a]** (20.0 ± 0.2), **[10d]** (22.0 ± 0.2), **[11b]** (22.0 ± 0.4), **[2]** (30.0 ± 0.6), **[15]** (36.4 ± 10.2), **[6]** (37.4 ± 10.2), **[9a]** (38.0 ± 1.8), **[10c]** (39.0 ± 1.8), **[13]** (42.6 ± 12.2), **[3]** (44.6 ± 12.6), **[10b]** (50.1 ± 0.7), **[11a]** (66.6 ± 12.2), **[17b]** (68.6 ± 12.2), **[7b]** (74.9 ± 0.9), **[5]** (75.7 ± 17.5).

"NCI-H460" [Doxorubicin] (0.0940 ± 0.0087), **[17a]** (8.3 ± 0.8), **[7a]** (10.4 ± 0.6), **[10a]** (10.8 ± 0.6), **[11a, 17b]** (12.0 ± 6.2), **[14b]** (14.5 ± 0.8), **[4]** (16.5 ± 0.8), **[2]** (19.3 ± 1.4), **[15]** (20.1 ± 0.8), **[6]** (22.1 ± 0.8), **[10b]** (23.2 ± 4.8), **[11b]** (26.3 ± 0.8), **[10d, 9b]** (30.6 ± 1.4), **[14a]** (32.6 ± 1.4), **[13, 3]** (32.6 ± 8.6), **[9a]** (40.0 ± 0.8), **[5]** (40.2 ± 12.8), **[7b]** (40.6 ± 1.8), **[10c]** (46.0 ± 0.8).

"SF–268" [Doxorubicin] (0.0940 ± 0.0070), **[17a]** (4.0 ± 0.8), **[7a]** (8.0 ± 0.4), **[6]** (14.9 ± 6.8), **[10a]** (16.5 ± 0.8), **[4, 14b]** (16.7 ± 1.6), **[10b]** (18.4 ± 1.8), **[15]** (18.9 ± 6.8), **[12]** (22.3 ± 0.5), **[9a,**

10c] (22.5 ± 1.1), **[11a, 17b]** (24.8 ± 3.2), **[2]** (26.3 ± 1.5), **[14a]** (36.4 ± 0.6), **[9b, 10d]** (38.4 ± 0.6), **[11b]** (39.0 ± 0.8), **[5]** (52.0 ± 9.0), **[7b]** (58.8 ± 0.8), **[3]** (60.4 ± 14.8), **[13]** (64.4 ± 14.8).

In general, compounds **17a**, **7a**, **14b**, **4**, and **10a** showed significant activity on the three tumor cell lines tested. The inhibitory effect of the other systems on tumor cell growth varied, according to the tested tumor cell, from high to medium or marginal effects. Some compounds had no impact on a specific tumor cell proliferation, while exhibited some specificity to the other. Thus compound **11a** revealed GI$_{50}$ ~ 66.6 µ/M towards MCF-7 tumor cell versus GI$_{50}$ ~ 12.0 µ/M for NCI-H460. Similarly, compound **12** had no effect on NCI-H460 tumor cell proliferation (GI$_{50}$ ~ 146 µ/M) while it showed high selectivity towards breast derived cells MCF-7 (GI$_{50}$ ~ 10.9 µ/M).

It is of interest that the pyrazole derivative **7a**, comprising one phenyl substituent, showed significant growth inhibition activity on the three tumor cell lines, compared to its counterpart **7b** with two phenyl functions. Also, comparing the 5-cyano pyridone derivative **17a** and its 5-ethoxy-carbonyl counterpart **17b**, it is obvious that the former has the highest inhibitory activity towards adenocarcinoma (MCF-7), while **17b** showed the lowest effect on the same tumor cell line.

3. Experimental

3.1. General

All melting points were determined on an Electrothermal digital melting point apparatus and are uncorrected. IR spectra (KBr discs) were recorded on a FTIR plus 460 or Pye Unicam SP-1000 spectrophotometer. ^{1}H-NMR spectra were recorded with Varian Gemini -200 (200 MHz) and Jeol AS 500 MHz instruments in DMSO-d6 as solvent using TMS as internal standard and chemical shifts are expressed as δ ppm. The mass spectra were recorded with Hewlett Packard 5988 A GC/MS system and GCMS-QP 1000 Ex Shimadzu instruments. Analytical data were obtained from the Micro-analytical Data Unit at Cairo University and were performed on Vario EL III Elemental CHNS analyzer.

3.2. Chemistry

3.2.1. 2-Cyano-*N*-(3-cyano-4,5,6,7-tetrahydrobenzo[*b*]thiophen-2-yl)-acetamide (**2**)

To a solution of 2-amino-3-cyano-4,5,6,7-tetrahydrobenzo[*b*]thiophene (**1**) (1.78 g, 0.01 mol) in dimethylformamide (30 mL), ethyl cyanoacetate (1.13 g, 0.01 mol) was added. The reaction mixture was heated under reflux for 5 h. The solid product formed upon pouring onto ice/water mixture was collected by filtration and crystallized from 1,4-dioxane. Pale yellow crystals, m.p. 129-130 °C, yield: 1.79 g (73%); Anal. For $C_{12}H_{11}N_3OS$ (245.30), (% Calcd./Found): 58.76/59.01 (C), 4.52/4.90 (H), 17.13/16.89 (N), 13.07/13.45 (S); IR (υ, cm^{-1}): 3,431-3,217 (NH), 3,090–3,010 (CH aromatic); 2,938–2,837 (CH$_2$), 2,262, 2,196 (2CN), 1,696 (C=O), 1,581, 1,434 (C=C); ^{1}H-NMR (δ, ppm): 1.70–2.60 (m, 8H, cyclohexene 4CH$_2$), 4.11 (s, 2H, CH$_2$), 6.94 (s, 1H, NH); MS *m/z* (%): 245 [M$^+$] (38.70), 178{[M$^+$ + 1] − [C$_3$H$_2$NO]$^+$}(75.80), 150 {[M$^+$] − [C$_4$H$_3$N$_2$O]$^+$} (100.00), 116 (11.80), 68 [C$_3$H$_2$NO]$^+$ (13.60).

3.2.2. 4-Amino-2-hydroxy-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-*b*] pyridine-3-carbonitrile (**3**)

A solution of **2** (2.45 g, 0.01 mol) in 1,4-dioxane (20 mL) containing triethylamine (2 mL) was heated under reflux for 5 h. The solid product formed upon pouring onto ice/water was collected by filtration, and crystallized from 1,4-dioxane. Brown crystals, m.p. 90–94 °C, yield: 1.52 g (65%); Anal. For $C_{12}H_{11}N_3OS$ (245.30), (% Calcd./Found): 58.76/58.77 (C), 4.52/4.85 (H), 17.13/17.00 (N), 13.07/13.30 (S); IR (υ, cm^{-1}): 3,432 (OH, enol form); 3,333–3,218 (NH, NH$_2$), 3,100 (CH aromatic), 2,934-2,839 (CH$_2$), 2,197 (CN), 1,621 (C=O, keto form), 1,574, 1,438 (C=C); ^{1}H-NMR (δ, ppm):1.75–2.55 (m, 8H, cyclohexene 4CH$_2$), 3.61 (s, 2H, NH$_2$), 6.97 (s, 1H, ring NH)); MS *m/z* (%): 245 [M$^+$] (100.00), 192 (90.35), 164 (35.09), 136 (93.72), 68 [C$_3$H$_2$NO]$^+$ (63.27).

3.2.3. Synthesis of the amide derivatives **4** and **5**.

To a solution of **2** (2.45 g, 0.01 mol) in 1,4-dioxane (25 mL) containing piperidine (1.00 mL) either salicylaldehyde (1.22 g, 0.01 mol) or benzaldehyde (1.06 g, 0.01 mol) was added. The reaction mixture, in each case, was heated under reflux for 5 h. The solid products formed upon pouring onto ice-water mixture containing few drops of hydrochloric acid was collected by filtration and crystallized from 1,4-dioxane.

N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-2-oxo-2H-chromen-3-il-carboxamide (**4**). Orange crystals, m.p. 271-273 C, yield: 2.63 g (75%); Anal. For $C_{19}H_{14}N_2O_3S$ (350.39), (% Calcd./Found): 65.13/64.76 (C), 4.03/4.32 (H), 7.99/8.25 (N), 9.15/9.27 (S); IR (υ, cm^{-1}): 3,324 (NH), 3,105–3,027 (CH aromatic), 2,928–2,857 (CH$_2$), 2,210 (CN), 1,715, 1,678 (2C=O), 1,569, 1,448 (C=C); ^{1}H-NMR (δ, ppm): 1.84–2.72 (m, 8H, cyclohexene 4CH$_2$), 6.94 (s, 1H, coumarin C4-H), 7.03–7.53 (m, 4H, C$_6$H$_4$), 8.50 (s, 1H, NH); MS *m/z* (%): 351 [M$^+$ + 1] (1.50), 350 [M$^+$] (8.40), 349 [M$^+$ − 1] (18.00), 316 (34.90) , 172 {[M$^+$ − 1] − [C$_9$H$_9$N$_2$S]$^+$} (100.00), 89 (67.80).

2-Cyano-N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-3-phenylacrylamide (**5**). Pale yellow crystals, m.p. 88-92 °C, yield: 2.50 g (75%); Anal. for $C_{19}H_{15}N_3OS$ (333.41), (% Calcd./Found): 68.45/ 68.11 (C), 4.53/4.80 (H), 12.60/12.46 (N), 9.62/9.98 (S); IR (υ, cm^{-1}): 3,348–3,210 (NH), 3,059 (CH aromatic), 2,933–,2855 (CH aliphatic, CH$_2$), 2,244, 2,214 (2CN), 1,620 (C=O), 1,571, 1,447 (C=C); ^{1}H-NMR (δ, ppm): 1.77–2.66 (m, 8H, cyclohexene 4CH$_2$), 6.87 (s, 1H, NH), 7.00–7.97 (m, 5H, C$_6$H$_5$), 8.56 (s, 1H, benzylidene CH); MS *m/z* (%): 333 [M$^+$] (12.50), 266 {[M$^+$ − 1] − [C$_3$NO]$^+$} (100.00), 238 (77.40), 66 [C$_3$NO]$^+$ (1.90), 77 [C$_6$H$_5$]$^+$ (33.40).

3.2.4. 2-Cyano-*N*-(3-cyano-4,5,6,7-tetrahydrobenzo[*b*]thiophen-2-yl)-3-phenylbut-2E-enamide (**6**).

To a mixture of equimolar amounts of **2** (2.45 g, 0.01 mol) and acetophenone (1.20 g, 0.01 mol), ammonium acetate (0.50 g) was added and the reaction mixture was heated in an oil bath 140 ^{o}C for 45 min. The reaction mixture was then boiled in ethanol (60 mL) for few minutes, poured onto ice/water mixture and the formed product was crystallized from ethanol. Pale brown crystals, m.p. 118–120 °C, yield: 2.08 g (60%); Anal. For $C_{20}H_{17}N_3OS$ (347.44), (% Calcd./Found): 69.14/69.40 (C), 4.93/5.12 (H), 12.09/12.07 (N), 9.23/9.51 (S); IR (υ, cm^{-1}): 3,428–3,220 (NH), 3,082-3,000 (CH aromatic), 2,935–2,840 (CH aliphatic), 2,216, 2,198 (2CN), 1,692 (C=O), 1,576, 1,438 (C=C); ^{1}H-

NMR (δ, ppm): 1.66-2.35 (m, 8H, cyclohexene 4CH$_2$), 1.87 (s, 3H, CH$_3$), 6.90 (s, 5H, C$_6$H$_5$), 11.50 (s, 1H, NH); MS *m/z* (%): 346 [M$^+$ − 1] (1.92), 178 {[M$^+$ + 1] − [C$_{11}$H$_8$NO]$^+$} (55.94), 150 {[M$^+$] − [C$_{12}$H$_9$N$_2$O]$^+$} (100.00), 116 (8.76), 77 [C$_6$H$_5$]$^+$ (14.92).

3.2.5. Synthesis of pyrazole carboxamide derivatives **7a,b**

To a solution of compound **4** (3.33 g, 0.01 mol) in 1,4-dioxane (25 mL) and dimethylformamide (10 mL), either hydrazine hydrate (0.50 g, 0.01 mol), or phenyl hydrazine (1.08 g, 0.01 mol) was added. The reaction mixture, in each case, was heated under reflux for 5 h. The solid products formed, in each case, upon pouring onto ice/water mixture containing few drops of hydrochloric acid were collected by filtration, and crystallized from 1,4-dioxane/dimethylformamide mixture.

3-Amino-N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-5-phenyl-1H-pyrazol-4-yl-carbox-amide (**7a**). Pale brown crystals, m.p. 231-235 °C, yield: 2.54 g (70%); Anal. For C$_{19}$H$_{17}$N$_5$OS (363.44), (% Calcd./Found): 62.79/63.18 (C), 4.71/5.05 (H), 19.27/19.33 (N), 8.82/9.20 (S); IR (υ, cm^{-1}): 3,445–3,220 (2NH, NH$_2$), 3,050 (CH aromatic), 2,929–2,848 (CH aliphatic, CH$_2$), 2,209 (CN), 1,622 (C=O), 1,550, 1,439 (C=C); ^{1}H-NMR (δ, ppm): 1.71–2.70 (m, 8H, cyclohexene 4CH$_2$), 3.90 (s, 2H, NH$_2$), 6.81 (s, 1H, NH), 7.17–7.86 (m, 5H, C$_6$H$_5$), 8.68 (s, 1H, NH).

3-Amino-N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-1,5-diphenyl-1H-pyrazol-4-yl-carboxamide (**7b**). Pale orange crystals, m.p. 128-130 °C, yield: 3.34 g (76%); Anal. For C$_{25}$H$_{21}$N$_5$OS (439.53), (% Calcd./Found): 68.32/68.00 (C), 4.82/4.53 (H), 15.93/15.63 (N), 7.30/7.62 (S); IR (υ, cm^{-1}): 3,452–3,225 (NH, NH$_2$), 3,056–3,028 (CH aromatic), 2,930-2,851 CH$_2$), 2,209 (CN), 1,621 (C=O), 1,597, 1,441 (C=C); ^{1}H-NMR (δ, ppm): 1.71–2.69 (m, 8H, cyclohexene 4CH$_2$), 3.90 (s, 2H, NH$_2$), 7.02-7.88 (m, 10H, 2C$_6$H$_5$), 10.29 (s, 1H, NH); MS *m/z* (%): 440 [M$^+$ + 1] (9.35), 439 [M$^+$] (12.03), 423 (83.97), 219 (100.00), 150 (42.43).

3.2.6. Synthesis of 3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl-functionalized pyridone derivatives **9a,b**.

Method (A): To a solution of **4** (3.33 g, 0.01 mol) in 1,4-dioxane (25 mL) and dimethylformamide (5 mL) containing triethylamine (1.00 mL), either malononitrile (0.66 g, 0.01 mol) or ethyl cyanoacetate (1.13 g, 0.01 mol) was added. The reaction mixture, in each case, was heated under reflux for 5 h, then cooled and neutralized by pouring onto ice/water mixture containing few drops of hydrochloric acid. The solid products formed, in each case, was filtered off and crystallized from 1,4-dioxane/dimethylformamide mixture.

Method (B): Equimolar amounts of **2** (2.45 g, 0.01 mol) and either benzylidene malononitrile (1.54 g, 0.01 mol) or benzylidene ethyl cyanoacetate (2.01g, 0.01 mol) in 1,4-dioxane (25 mL) and dimethylformamide (5 mL) containing triethylamine (1.00 mL) were heated under reflux for 5 h. The reaction mixture in each case was treated in a similar manner as in method A.

6-Amino-1-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-2-oxo-4-phenylpyridine-3,5-dicarbonitrile (**9a**). Pale yellow crystals, m.p. > 300 °C, yield: (2.98 g 75%, method A; 3.18 g 80% method B); Anal. For C$_{22}$H$_{15}$N$_5$OS (397.45), (% Calcd./Found): 66.48/66.88 (C), 3.80/3.90 (H), 17.62/17.38 (N) ,

8.07/8.30 (S); IR (*v*, cm^{-1}): 3,307, 3,218 (NH$_2$), 3,061 (CH aromatic); 2,938-2,862 (CH$_2$), 2,253, 2,223, 2,209 (3CN), 1,632 (C=O), 1,572, 1,484 (C=C); ^{1}H-NMR (δ, ppm): 1.88-2.55 (m, 8H, cyclohexene 4CH$_2$), 3.61 (s, 2H, NH$_2$), 7.54–7.63 (m, 5H, C$_6$H$_5$); MS *m/z* (%): 399 [M$^+$ + 2] (13.30), 398 [M$^+$ + 1] (21.30), 397 [M$^+$] (100.00), 199 (14.90), 150 (12.80), 119 (11.70).

Ethyl 2-amino-5-cyano-1-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-1,6-dihydro-6-oxo-4-phenylpyridine-3-carboxylate (**9b**). Pale yellow crystals, m.p. > 300 °C, yield: (3.24 g 73%, method A; 3.82 g 86 %, method B); Anal. For C$_{24}$H$_{20}$N$_4$O$_3$S (444.51), (% Calcd./Found): 64.85/65.00 (C), 4.54/4.92(H), 12.60/12.21 (N), 7.21/7.43 (S); IR (υ, cm^{-1}): 3,326-3,214 (NH$_2$), 3,060 (CH aromatic), 2,933-2,855 (CH$_2$, CH$_3$), 2,218, 2,204 (CN), 1,695, 1,634 (2C=O), 1,573, 1,446 (C=C); ^{1}H-NMR (δ, ppm): 1.21(t, *J* = 8.00 Hz, 3H, CH$_3$), 1.82-2.73 (m, 8H, cyclohexene 4CH$_2$), 3.41 (s, 2H, NH$_2$), 4.30 (q, *J* = 8.00 Hz, 2H, CH$_2$), 6.98–8.02 (m, 5H, C$_6$H$_5$); MS *m/z* (%): 444 [M$^+$] (43.15), 407 (66.02), 242 (80.91), 198 (79.73), 73 (72.50), 61 (100.00).

3.2.7. Synthesis of 3-cyano-4,5,6,7-tetrahydrobenzo[*b*]-thiophen-2-yl-functionalized 2-pyridone derivatives **10a-d**.

The procedure adopted for the synthesis of **9a,b** (Method A) was followed using **2** (2.45 g, 0.01 mol) and either malononitrile (0.66 g, 0.01 mol), ethyl cyanoacetate (1.13 g, 0.01 mol), acetyl acetone (1.00 g, 0.01 mol) or ethyl acetoacetate (1.33 g, 0.01 mol). The solid products formed, in each case, upon treating of the reaction mixtures was crystallized from ethanol/dimethylformamide mixture.

4,6-Diamino-1-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-1,2-dihydro-2-pyridone-3-carbonitrile (**10a**). Brown crystals, m.p. 215-218 °C, yield: 2.33 g (75%); Anal. For C$_{15}$H$_{13}$N$_5$OS (311.36), (% Calcd./Found): 57.86/58.04 (C), 4.21/4.50 (H), 22.49/ 22.10 (N), 10.30/10.62 (S); IR (υ, cm^{-1}): 3,430–3,217 (2NH$_2$), 3,010 (CH aromatic), 2,936–2,836 (CH$_2$), 2,250, 2,195 (2CN), 1,620 (C=O), 1,574, 1,433 (C=C); ^{1}H-NMR (δ, ppm): 1.70–2.69 (m, 8H, cyclohexene 4CH$_2$), 2.91, 2.98 (2s, 4H, 2NH$_2$), 7.89 (s, 1H, pyridine C5-H); MS *m/z* (%): 311 [M$^+$] (49.14), 296 {[M$^+$ + 1] − (NH$_2$)} (55.49), 282 {[M$^+$ + 3] − (2NH$_2$)} (46.55), 136 (77.59), 60 (100.00).

4-Amino-1-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-6-hydroxy-1,2-dihydro-2-pyridone-3-carbonitrile (**10b**). Pale yellow crystals, m.p. 277–280 °C, yield: 2.00 g (64%); Anal. For C$_{15}$H$_{12}$N$_4$O$_2$S (312.34), (% Calcd./Found): 57.68/57.83 (C), 3.87/4.22 (H), 17.94/17.54 (N), 10.27/10.50 (S); IR (υ, cm^{-1}): 3,431 (OH), 3,334–3,224 (NH$_2$), 3,093 (CH aromatic), 2,935–2,840, (CH$_2$), 2,219, 2,199 (2CN), 1,694 (C=O), 1,581, 1,438 (C=C); ^{1}H-NMR (δ, ppm): 1.79-2.64 (m, 8H, cyclohexene 4CH$_2$), 4.11 (s, 2H, NH$_2$), 6.92 (s, 1H, pyridine C5-H), 11.89 (s, 1H, OH); MS *m/z* (%): 312 [M$^+$] (19.44), 311 [M$^+$ − 1] (100.00), 296 {[M$^+$] − (NH$_2$)} (49.67), 285 {[M$^+$ − 1] − [CN]$^+$} (30.17), 219 {[M$^+$ + 1] − [C$_4$H$_2$N$_2$O]$^+$} (73.86), 164 {[M$^+$ + 3] − [C$_6$H$_5$N$_3$O$_2$]$^+$} (66.06).

1-(3-Cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-4,6-dimethyl-1,2-dihydro-2-pyridone-3-carbonitrile (**10c**). Brown crystals, m.p. 130–135 °C, yield: 2.25 g (73%); Anal. For C$_{17}$H$_{15}$N$_3$OS (309.39), (% Calcd./Found): 66.00/66.20 (C), 4.89/5.19 (H), 13.58/13.48 (N), 10.36/ 10.51 (S); IR (υ, cm^{-1}): 3,074 (CH aromatic), 2,933, 2,851 (CH$_2$, CH$_3$), 2,215, 2,230 (2CN), 1,667 (C=O), 1,572, 1,439 (C=C); ^{1}H-

NMR (δ, ppm): 1.77-2.60 (m, 8H, cyclohexene 4CH$_2$), 2.11, 2.36 (2s, 6H, 2CH$_3$), 6.51 (s, 1H, pyridine C5-H); MS *m/z* (%): 311 [M$^+$ + 2] (7.58), 310 [M$^+$ + 1] (20.59), 309 [M$^+$] (100.00), 281 {[M$^+$ − 2] − [CN]$^+$} (74.34), 162 [C$_9$H$_8$NS]$^+$ (28.01), 147 [C$_8$H$_7$N$_2$O]$^+$ (5.08), 131 {[M$^+$] − [C$_9$H$_{10}$N$_2$S]} (38.92).

1-(3-Cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-6-hydroxy-4-methyl-1,2-dihydro-2-pyridone-3-carbonitrile (**10d**). Pale brown crystals, m.p. 251–255 °C, yield: 2.02 g (65%); Anal. For C$_{16}$H$_{13}$N$_3$O$_2$S (311.35), (% Calcd./Found): 61.72/61.52 (C), 4.21/4.30 (H), 13.50/13.87 (N), 10.30/10.64 (S); IR (υ, cm^{-1}): 3,445-3,225 (OH), 2,931-2,850 (CH$_2$, CH$_3$), 2,220, 2,209 (CN), 1,668 (C=O), 1,574, 1,440 (C=C); ^{1}H-NMR (δ, ppm): 1.82-2.94 (m, 8H, cyclohexene 4CH$_2$), 2.55 (s, 3H, CH$_3$), 6.88 (s, 1H, pyridine C5-H), 12.10 (s, 1H, OH); MS *m/z* (%): 313 [M$^+$ + 2] (1.08), 312 [M$^+$ + 1] (0.75), 311 [M$^+$] (0.80), 219 {[M$^+$ + 1] − [C$_5$H$_3$NO]$^+$} (100.00), 163 [C$_9$H$_9$NS]$^+$ (13.47), 150 [C$_7$H$_6$N$_2$O$_2$]$^+$ (48.18).

3.2.8. Synthesis of (3-cyano-4,5,6,7-tetrahydrobenzo[*b*]thiophen-2-yl)- functionalized thiophene-derivatives **11a,b** and the thiazole derivative **12**.

To a solution of compound **2** (2.45 g, 0.01 mol) in 1,4-dioxane (25 mL) containing triethylamine (1.00 mL), either malononitrile (0.66 g, 0.01 mol), ethyl cyanoacetate (1.13 g, 0.01 mol) or phenyl isothiocyanate (1.35 g, 0.01 mol) was added followed by the addition of an equimolar amount of elemental sulfur (0.32 g, 0.01 mol). The reaction mixture was heated under reflux for 5 h, then cooled and neutralized by pouring onto ice/water mixture containing few drops of hydrochloric acid. The solid product formed in each case was collected by filtration and crystallized from dimethylformamide.

3,5-Diamino-4-cyano-N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)thiophene-2-carboxamide (**11a**). Brown crystals, m.p. > 300 °C, yield: 2.06 g (60%); Anal. For C$_{15}$H$_{13}$N$_5$OS$_2$ (343.43), (% Calcd./Found): 52.46/52.80 (C), 3.82/3.73 (H), 20.39/20.16 (N), 18.67/18.41 (S); IR (υ, cm^{-1}): 3431–3216 (NH, 2NH$_2$), 2,933-2,841 (CH$_2$), 2,202, 2,195 (2CN), 1,632 (C=O), 1,572, 1,407 (C=C); ^{1}H-NMR (δ, ppm): 1.67–2.49 (m, 8H, cyclohexene 4CH$_2$), 3.34, 3.38 (2s, 4H, 2NH$_2$), 6.90 (s, 1H, NH); MS *m/z* (%): 346 [M$^+$ + 3] (0.88), 178 [C$_9$H$_{10}$N$_2$S] (39.83), 163 (1.58), 150 [C$_8$H$_8$NS]$^+$ (100.00), 60 (10.38).

Ethyl 5-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl-carbamoyl)-2,4-diaminothiophene-3-carboxylate (**11b**). Brown crystals, m.p. 163-166 °C, yield: 2.54 g (65%); Anal. For C$_{17}$H$_{18}$N$_4$O$_3$S$_2$ (390.47), (% Calcd./Found): 52.29/52.00 (C), 4.65/4.46 (H), 14.35 / 14.00 (N), 16.42/16.81 (S); IR (υ, cm^{-1}): 3,324–3,221 (NH, 2NH$_2$), 2,929, 2,848 (CH$_2$, CH$_3$), 2,205 (CN), 1,696, 1,625 (2C=O), 1,571, 1,438 (C=C); ^{1}H-NMR (δ, ppm): 1.12 (t, *J* = 7.00 Hz, 3H, CH$_3$), 1.72-2.50 (m, 8H, cyclohexene 4CH$_2$), 3.31, 3.35 (2s, 2H each, 2NH$_2$), 3,49 (q, *J* = 7.00 Hz, 2H, CH$_2$), 6.90 (s, 1H, NH); MS *m/z* (%): 392 [M$^+$ + 2] (36.61), 391 [M$^+$ + 1] (8.09), 362 {[M$^+$] − [CH$_2$N]$^+$} (100.00), 178 [C$_9$H$_{10}$N$_2$S] (14.57), 150 [C$_8$H$_8$NS]$^+$ (28.83), 127 (77.20).

4-Amino-N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-2,3-dihydro-3-phenyl-2-thioxothiazol-5-yl-carboxamide (**12**). Dark brown crystals, m.p. 103-105 °C, yield: 3.01 g (73%); Anal. For C$_{19}$H$_{16}$N$_4$OS$_3$ (412.55), (% Calcd./Found): 55.32/55.51 (C), 3.91/3.85 (H), 13.58/13.34 (N), 23.32/23.15 (S); IR (υ, cm^{-1}): 3,319 (NH, NH$_2$), 2,927–2,847 (CH$_2$), 2,201 (CN), 1,632 (C=O), 1,539, 1,437 (C=C), 1,327, 1,282 (C=S); ^{1}H-NMR (δ, ppm): 1.72-2.85 (m, 8H, cyclohexene 4CH$_2$), 3.41 (s,

2H, NH$_2$), 7.10–7.59 (m, 5H, C$_6$H$_5$), 7.92 (s, 1H, NH); MS *m/z* (%): 412 [M$^+$] (0.23), 178 [C$_9$H$_{10}$N$_2$S] (62.74), 150 [C$_8$H$_8$NS]$^+$ (74.81), 126 (84.47), 93 [Ph-NH$_2$] (100.00), 77 [C$_6$H$_5$]$^+$ (29.64).

3.2.9. *2-(4-Amino-2,3-dihydro-6-oxo-3-phenyl-2-thioxopyrimidin-1(6H)-yl)-4,5,6,7-tetrahydrobenzo[b] thiophene-3-carbonitrile* (**13**).

Equimolar amounts of **2** (2.45 g, 0.01 mol) and phenyl isothiocyanate (1.35 g, 0.01 mol) in 1,4-dioxane (20 mL) containing triethylamine (1.0 mL) were heated under reflux for 5h. After cooling, the reaction mixture was acidified by hydrochloric acid and the crude product was precipitated, collected by filtration and crystallized from dimethylformamide. Pale yellow crystals, m.p. > 300 °C, yield: 3.04 g (80%); Anal. For C$_{19}$H$_{16}$N$_4$OS$_2$ (380.49), (% Calcd./Found): 59.98/59.60 (C), 4.24/4.27 (H), 14.73/ 14.33 (N), 16.85/17.20 (S); IR (υ, cm^{-1}): 3,442–3,242 (NH$_2$), 3,056 (CH aromatic), 2,931, 2,837 (CH$_2$), 2,206 (CN), 1,607 (C=O), 1,561, 1,498 (C=C); 1,373, 1,280 (C=S); ^{1}H-NMR (δ, ppm): 1.88–2.70 (m, 8H, cyclohexene 4CH$_2$), 3.83 (s, 2H, NH$_2$), 6.92 (s, 1H, pyrimidine C3-H), 7.12-7.62 (m, 5H, C$_6$H$_5$); MS *m/z* (%): 382 [M$^+$ + 2] (8.20), 313 {[M$^+$ + 2] − [C$_3$H$_3$NO]$^+$} (100.00), 255 {[M$^+$ + 1] − [C$_4$H$_2$N$_2$OS]$^+$} (37.00), 226 (11.00), 147 (11.60), 126 (19.20).

3.2.10. Synthesis of the 3-cyano-4,5,6,7-tetrahydrobenzo[*b*]thiophen-2-yl-functionalized thiophene derivatives **14a,b** and the thiazole **15** derivative.

Equimolar amounts of **2** (2.45 g, 0.01 mol) and phenyl isothiocyanate (1.35 g, 0.01 mol) in dimethylformamide (20 mL) and potassium hydroxide were stirred overnight, then added ethyl chloroacetate (1.22 g, 0.01 mol), phenacyl bromide (1.99 g, 0.01 mol), or chloroacetone (0.92 g, 0.01 mol) while stirring overnight. The solid products formed upon pouring onto ice/water mixture containing few drops of hydrochloric acid were collected by filtration and crystallized from 1,4-dioxane.

Ethyl 3-amino-4-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl-carbamoyl)-5-(phenylamino)-thio-phene-2-carboxylate (**14a**). Dark green crystals, m.p. 102–105 °C, yield: 4.57 g (98%); Anal. For C$_{23}$H$_{22}$N$_4$O$_3$S$_2$ (466.57), (% Calcd./Found): 59.21/58.90 (C), 4.75/4.68 (H), 12.01/11.97 (N), 13.74/ 14.00 (S); IR (υ, cm^{-1}): 3,368–3,186 (2NH, NH$_2$), 3,061 (CH aromatic), 2,931–2,857 (CH$_2$, CH$_3$), 2,208 (CN), 1,735, 1,655 (2C=O), 1,570, 1,497 (C=C); ^{1}H-NMR (δ, ppm): 1.21 (t, *J* = 8.00 Hz, 3H, CH$_3$), 1.76–2.91 (m, 8H, cyclohexene 4CH$_2$), 4.07 (q, *J* = 8.00 Hz, 2H, CH$_2$), 4.37 (s, 2H, NH$_2$), 6.94 (s, 1H, NH), 7.14-7.96 (m, 5H, C$_6$H$_5$), 9.99 (s, 1H, NH); MS *m/z* (%): 466 [M$^+$] (0.51), 353 (72.06), 243 (70.07), 215 (82.33), 178 [C$_9$H$_{10}$N$_2$S] (31.66), 150 [M$^+$] − [C$_{15}$H$_{14}$N$_3$O$_3$S]$^+$ (40.22), 77 [C$_6$H$_5$]$^+$ (100.00).

3-Amino-2-benzoyl-4-[(3-cyano-4,5,6,7-tetrahydrobenzo-[b]thiophene-2-carbonyl)-amino]-5-phenyl-aminothiophene (**14b**). Dark orange crystals, m.p. 94–96 °C, yield: 4.89 g (98%); Anal. For C$_{27}$H$_{22}$N$_4$O$_2$S$_2$ (498.62), (% Calcd./Found): 65.04/64.92 (C), 4.45/4.17 (H), 11.24/10.95 (N),12.86/ 12.97 (S); IR (υ, cm^{-1}): 3,318 (2NH, NH$_2$); 3,058(CH aromatic); 2,927-2,847 (CH$_2$); 2,203 (CN); 1,720, 1,636 (2C=O); 1,549, 1,485 (C=C); ^{1}H-NMR (δ, ppm): 1.81–2.55 (m, 8H, cyclohexene 4CH$_2$), 4.80 (s, 2H, NH$_2$), 7.38-8.03 (m, 10H, 2C$_6$H$_5$), 8.91, 9.83 (2s, 2H, 2NH); MS *m/z* (%): 498 [M$^+$] (3.9), 255 (13.20), 178 [C$_9$H$_{10}$N$_2$S] (8.70), 150 [M$^+$] − [C$_{19}$H$_{14}$N$_3$O$_2$S]$^+$ (5.80), 134 (13.50), 77 [C$_6$H$_5$]$^+$ (100.00).

2-Cyano-N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-2-(4-methyl-3-phenyl-3H-thiazol-2-yl-idene)-acetamide (**15**). Dark reddish brown crystals, m.p. 222–226 °C, yield: 4.14 g (99%); Anal. For $C_{22}H_{18}N_4OS_2$ (418.54), (% Calcd./Found): 63.13/62.81 (C), 4.33/4.36 (H), 13.39/13.54 (N), 15.32/15.13 (S); IR (υ, cm^{-1}): 3,370 (NH), 3,058 (CH aromatic), 2,926-2,845 (CH$_3$), 2,203, 2,173 (CN), 1,640 (C=O), 1,542, 1,467 (C=C); ^{1}H-NMR (δ, ppm): 1.38 (s, 3H, CH$_3$); 1.79-2.50 (m, 8H, cyclohexene 4CH$_2$), 6.67 (s, 1H, thiazole C5-H), 7.09-8.00 (m, 5H, C$_6$H$_5$), 9.82 (s, 1H, NH); MS *m/z* (%): 419 [M$^+$ + 1] (2.90), 418 [M$^+$] (4.90), 417 [M$^+$ − 1] (4.40), 323 (35.40), 241 [M$^+$ + 1] − [C$_9$H$_{10}$N$_2$S] (100.00),178 [C$_9$H$_{10}$N$_2$S] (22.80), 150 [M$^+$] − [C$_{14}$H$_{10}$N$_3$OS]$^+$ (21.40), 77 [C$_6$H$_5$]$^+$ (93.70).

3.2.11. *2-Cyano-2-(2-phenylhydrazono)-N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-acetamide* (**16**)

To a cold solution (0–5 °C) of **2** (2.45 g, 0.01 mol), in ethanol (20 mL) containing sodium hydroxide (1.00 g) an equimolar amount of diazotized aniline was gradually added while stirring. The solid product formed upon cooling in an ice-bath was collected by filtration, washed with water and crystallized from 1,4-dioxane. Reddish brown crystals, m.p. 128–132 °C, yield: 2.27 g (65%); Anal. For $C_{18}H_{15}N_5OS$ (349.41), (% Calcd./Found): 61.87/62.20 (C), 4.33/4.44 (H), 20.04/19.70 (N), 9.18/9.39 (S); IR (υ, cm^{-1}): 3,364–3,228 (2NH), 3,135–3,066 (CH aromatic), 2,929, 2,850 (CH$_2$), 2,258, 2,209 (2CN), 1,682 (C=O), 1,601, 1,493 (C=C), 1,545 (=N-NH); ^{1}H-NMR (δ, ppm): 1.75-2.50 (m, 8H, cyclohexene 4CH$_2$), 6.95-7.86 (m, 5H, C$_6$H$_5$), 9.14, 10.88 (2s, 1H each, 2NH); MS *m/z* (%): 350 [M$^+$ + 1] (4.83), 349 [M$^+$] (17.97), 178 {[M$^+$ + 1] − [C$_9$H$_6$N$_3$O]$^+$} (100.00), 167 {[M$^+$ + 5] − [C$_9$H$_7$N$_4$O]$^+$} (34.12), 149 {[M$^+$ − 1] − [C$_{10}$H$_7$N$_4$O]$^+$} (80.25), 105 (23.09), 77 [C$_6$H$_5$]$^+$ (60.98).

3.2.12. Synthesis of 3-phenylazo-2-pyridone derivatives **17a,b**

To a solution of **16** (3.49 g, 0.01 mol) in ethanol (25 mL) and dimethylformamide (5 mL) containing triethylamine (1.00 mL), either of malononitrile (0.66 g, 0.01 mol) or ethyl cyanoacetate (1.13 g, 0.01 mol) was added. The reaction mixture, in each case, was heated under reflux for 5 h, then cooled and neutralized by pouring onto ice/water mixture containing few drops of hydrochloric acid. The solid products formed, in each case, was filtered off and crystallized from ethanol/dimethylformamide mixture.

5-(2-phenyldiazenyl)-2,4-diamino-1-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-1,6-dihydro-6-oxopyridine-3-carbonitrile (**17a**). Dark orange crystals, m.p. 200–205 °C, yield: 3.49 g (84%); Anal. For $C_{21}H_{17}N_7OS$ (415.47), (% Calcd./Found): 60.71/61.10 (C), 4.12/4.50 (H), 23.60/23.30 (N), 7.72/7.92 (S); IR (υ, cm^{-1}): 3,356-3,223 (2NH$_2$), 3,135–3,063 (CH aromatic), 2,931-2,853 (CH$_2$), 2,253, 2,208 (2CN), 1,681 (C=O), 1,600, 1,490 (C=C); ^{1}H-NMR (δ, ppm): 1.66–2.60 (m, 8H, cyclohexene 4CH$_2$), 3.13, 3.39 (2s, 4H, 2NH$_2$), 7.13-7.64 (m, 5H, C$_6$H$_5$); MS *m/z* (%): 415 [M$^+$] (20.58), 349 {[M$^+$] − [C$_3$H$_2$N$_2$]$^+$} (63.71), 178 {[M$^+$ + 2] − [C$_{12}$H$_9$N$_5$O]$^+$} (100.00), 148 [C$_6$H$_4$N$_4$O]$^+$ (40.10), 106 [C$_6$H$_6$N$_2$]$^+$ (37.06), 66 [C$_3$H$_2$N$_2$]$^+$ (6.08).

2-(4,6-Ethyl 5-(2-phenyldiazenyl)-2,4-diamino-1-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-1,6-dihydro-6-oxopyridine-3-carboxylate (**17b**). Dark orange crystals, m.p. 166–170 °C, yield: 2.77 g

(60%); Anal. For $C_{23}H_{22}N_6O_3S$ (462.52), (% Calcd./Found): 59.73/60.00 (C), 4.79/5.03 (H),18.17/ 17.95 (N), 6.93/7.30 (S); IR (υ, cm^{-1}): 3,355–3,222 (2NH$_2$), 3,060 (CH aromatic), 2,931–2,850 (CH$_2$, CH$_3$), 2,206 (CN), 1,739, 1,677 (2C=O), 1,598, 1,455 (C=C); ^{1}H-NMR (δ, ppm): 1.20 (t, J = 7.65 Hz, 3H, CH$_3$), 1.72-2.54 (m, 8H, cyclohexene 4 CH$_2$), 3.07, 3.08 (2s, 2H each, 2NH$_2$), 4.13 (q, J = 7.65 Hz, 2H, CH$_2$), 7.14-7.81 (m, 5H, C$_6$H$_5$); MS *m/z* (%): 462 [M$^+$] (38.76), 349 {[M$^+$] − [C$_5$H$_7$NO$_2$]$^+$} (44.53), 181 (51.72), 167 (66.72), 133 [C$_6$H$_3$N$_3$O]$^+$ (100.00), 113 (35.91).

3.3. Biology

Materials and methods: Fetal bovine serum (FBS) and L-glutamine, were obtained from Gibco Invitrogen Company (Scotland, UK). RPMI-1640 medium was provided from Cambrex (New Jersey, USA). Dimethyl sulfoxide (DMSO), doxorubicin, penicillin, streptomycin and sulforhodamine B (SRB) were obtained from Sigma Chemical Company. (Saint Louis, MO, USA).

Samples: Stock solutions of compounds **2-17b** were prepared in DMSO and kept at −20 ^{o}C. Appropriate dilutions of the compounds were freshly prepared just prior the assays. Final concentrations of DMSO did not interfere with the cell growth.

Cell cultures: Three human tumor cell lines, MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer), and SF-268 (CNS cancer) were used. MCF-7 was obtained from the European Collection of Cell Cultures (ECACC, Salisbury, UK) and NCI-H460 and SF-268 were kindly provided by the National Cancer Institute (NCI, Cairo, Egypt). They grow as monolayer and routinely maintained in RPMI-1640 medium supplemented with 5% heat inactivated FBS, 2 mM glutamine and antibiotics (penicillin 100 U/mL, streptomycin 100 μg/mL), at 37 ^{o}C in a humidified atmosphere containing 5% CO$_2$. Exponentially growing cells were obtained by plating 1.5 × 10^5 cells/mL for MCF-7 and SF-268 and 0.75 × 10^4 cells/mL for NCI-H460, followed by 24 h of incubation. The effect of the vehicle solvent (DMSO) on the growth of these cell lines was evaluated in all the experiments by exposing untreated control cells to the maximum concentration (0.5%) of DMSO used in each assay.

4. Conclusions

In summary, we have developed a convenient synthetic approach to 22 novel highly substituted and polyfunctionalized heterocyclic systems based on 2-cyano-*N*-(3-cyano-4,5,6,7-tetrahydrobenzo[*b*]-thiophen-2-yl)-acetamide. The regioselective attack by different reagents on the cyanoacetamido moiety in the key precursor **2** led to the diversity of the produced systems. All compounds were assessed for their antiproliferative activities on three human cancer cell lines. Most of the systems were found to be promising antiproliferative agents. As a continuation of this work which provides guidance for the development of other new systems based on functionalized 4,5,6,7-tetrahydrobenzo[*b*]-thiophene core, we intended to study other related systems and the results of further pharmacological investigations will be reported in due course.

Acknowledgement

References and Notes

1. Chobot, V.; Vytlačilová, J.; Kubicová, L.; Opletal, L.; Jahodář, L.; Laaskso, I.; Vuorela, P. Phototoxic activity of a thiophene polyacetylene from *Leuzea carthamoides*. *Fitoterapia* **2006**, *77*, 194-198.

2. Tor, Y.; Valle, S.D.; Jaramillo, D.; Srivatsan, S.G.; Rios, A.; Weizman, H. Designing new isomorphic fluorescent nucleobase analogues : the thieno[3,2-*d*]pyrimidine core. *Tetrahedron* **2007**, *63*, 3608-3614.

3. Okutan, M.; Yerli, Y.; San, S.E.; Yilmaz, F.; Günaydin, O.; Durak, M. Dielectric properties of thiophene based conducting polymers. *Syn. Metals* **2007**, *157*, 368-373.

4. Ogawa, S.; Muraoka, H.; Kikuta, K.; Saito, F.; Sato, R. Design of reversible multi-electron redox systems using benzochalcogenophenes containing aryl and/or ferrocenyl fragments. *J. Organometal. Chem.* **2007**, *692*, 60-69.

5. Destri, S.; Giovanella, U.; Fazio, A.; Porzio, W.; Gabriele, B.; Zotti, G. Poly(bithiophene)-co-3,4-di(methoxycarbonyl)methyl thiophene for LED. *Org. Electron.* **2002**, *3*, 149-156.

6. Bouachine, M.; Benaqqa, O.; Toufik, H.; Hamidi, M.; Lère-Porte, J.-P.; Serein-Spirau, F.; Amine, A. Experimental and quantum chemical investigation of new electroluminescent material based on thiophene, phenylene and antracene. *Analele Universităţii din Bucureşti* **2010**, *19*, 35-44.

7. Batista, R.M.F.; Costa, S.P.G.; Belsley, M.; Lodeiro, C.; Raposo, M.M.M. Synthesis and characterization of novel (oligo)thienyl-imidazo-phenanthrolines as versatile π conjugated systems for several optical applications. *Tetrahedron* **2008**, *64*, 9230-9238.

8. Jarvest, R.L.; Pinto, I.L.; Ashman, S,M.; Dabrowski, C.E.; Fernandez, A.V.; Jennings, L.J.; Lavery, P.; Tew, D.G. Inhibition of herpes proteases and antiviral activity of 2-substituted thieno[2,3-*d*]oxazinones. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 443-448.

9. Wardakhan, W.W.; Shams. H.Z.; Moustafa, H.E. Synthesis of polyfunctionally substituted thiophene, thieno [2,3-*b*]pyridine and thieno[2,3-*d*]pyrimidine derivatives. *Phosph. Sulf. Silicon* **2005**, *180*, 1815-1827.

10. Isabel C.F.R., Ricardo C. C., Letícia M. E., Maria-João R.P.Q. Screening of antimicrobial activity of diarykamines in the 2,3,5-trimethylbenzo[*b*]thiopheneseries: a structure-activity evaluation study. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 5831-5833.

11. Pinto, E.; Queiroz, M.-J.R.P.; Vale-Silva, L.A.; Oliveira, J.F.; Begouin, A.; Begouin, J.-M.; Kirsch, G. Antifungal activity of synthetic di(hetero)arylamines based on the benzo[*b*]thiophene moiety. *Bioorg. Med. Chem.* **2008**, *16*, 8172-8177.

12. Dannhardt, G.; Kiefer, W.; Krämer, G.; Maehrlein, S.; Nowe, U.; Fiebich, B. The pyrrole moiety as a template for COX-1/COX-2 inhibitors. *Eur. J. Med. Chem.* **2000**, *35*, 499-510.

13. Brault, L.; Migianu, E.; Néguesque, A.; Battaglia, E.; Bagrel, D.; Kirsch, G. New thiophene analogues of kenpaullone: synthesis and biological evaluation in breast cancer cells. *Eur. J. Med. Chem.* **2005**, *40*, 757-763.

14. Starčević, K.; Karminski-Zamola, G.; Piantanida, I.; Zinić, M.; Šuman, L.; Kralj, M. Photoinduced switch of a DNA/RNA inactive molecule into a classical intercalator. *J. Am. Chem. Soc.* **2005**,*127*, 1074-1075.

15. Romagnoli, R.; Baraldi, P.G.; Carrion, M.D.; Cara, C.L.; Cruz-Lopez, O.; Preti, D.; Tolomeo, M.; Grimaudo, S.; Cristina, A.D.; Zonta, N.; Balzarini, J.; Brancale, A.; Sarkar, T.; Hamel, E. Design, synthesis and biological evaluation of thiophene analogues of chalcones. *Bioorg. Med. Chem.* **2008**, *16*, 5367-5376.

16. Ferreira, I.C.F.R.; Queiroz, M.R.P.; Vilas-Boas, M.; Estevinho, L. M.; Begouin, A.; Kirsch G. Evaluation of the antioxidant properties of diarylamines in benzo[*b*]thiophene series by free radical scavenging activity and reducing power, *Bioorg. Med. Chem. Lett.* **2006**, *16*, 1384-1387.

17. Pinto, I.L.; Jarvest, R.L.; serafinowska, H.T. The synthesis of 5-alkoxy and 5-amino substituted thiophenes. *Tetrahedron Lett.* **2000**, *41*, 1597-1600.

18. Baraldi, P.G.; Pavani, M.G.; Shryock, J.C.; Moorman, A.R.; Iannotta, V.; Borea, P.A.; Romagnoli, R. Synthesis of 2-amino-3-heteroaroylthiophenes and evaluation of their activity as potential allosteric enhancers at the human A_1 receptor. *Eur. J. Med. Chem.* **2004**, *39*, 855-865.

19. Pillai, A.D.; Rathod, P.D.; Xavier, F.P.; Vasu, K.K.; Padh, H.; Sudarsanam, V. Design, synthesis, and pharmacological evaluation of some 2-[4-morpholino]-3-aryl-5-substituted thiophenes as novel anti-inflammatory agents: generation of a novel anti-inflammatory pharmacophore. *Bioorg. Med. Chem.* **2004**, *12*, 4667-4671.

20. Moghaddam, F.M.; Zali-Boinee, H. A versatile one-pot synthesis of 2,3,5-tri-substituted thiophenes from thiomorpholides. *Tetrahedron Lett.* **2003**, *44*, 6253-6255.

21. Jones, R.J.; Cava, M.P. Photocyclisation strategy for the synthesis of antitumour agent CC-1065: synthesis of thiophene analogues of PDE-I and PDE-II. *J. Chem. Soc. Chem. Commun.* **1986**, 826-827.

22. Starčević, K.; Kralj, M.; Piantanida, I.; Šuman, L.; Pavelić, K.; Karminski-Zamola, G. Synthesis, photochemical synthesis, DNA binding and antitumor evaluation of novel cyano- and amidino-substituted derivatives of naphtho-furans, naphtho-thiophenes, thieno-benzofurans, benzo-dithiophenes and their acyclic precursors. *Eur. J. Med. Chem.* **2006**, *41*, 925-939.

23. James, B.; Suresh, E.; Nair, M.S. Friedel-Crafts alkylation of a cage enone: synthesis of aralkyl substituted tetracyclo[5.3.1.0$^{[2,6]}$.0$^{[4,8]}$]undeca-9,11-diones and the formation of fascinating novel cage compounds with pyrrole and thiophene using Montmorillonite K-10. *Tetrahedron Lett.* **2007**, *48*, 6059-6063.

24. Kondolff, I.; Doucet, H.; Santelli, M. Synthesis of biheteroaryl derivatives by tetraphosphine/palladium-catalysed Suzuki coupling of heteroaryl bromides with heteroarylboronic acids. *J. Mol. Catal. A: Chem.* **2007**, *269*, 110-118.

25. Queiroz, M.-J.R.P.; Ferreira, I.C.F.R.; Gaetano, Y.D.; Kirsch, G.; Calhelha, R.C.; Estevinho, L.M. Synthesis and antimicrobial activity studies of orthochlorodiarylamines and heteroaromatic tetracyclic systems in the benzo[*b*]thiophene series. *Bioorg. Med. Chem.* **2006**, *14*, 6827-6831.

26. Quèiroz, M.-J.R.P.; Ferreira, I.C.F.R.; Calhelha, R.C.; Estevinho, L.M. Synthesis and antioxidant activity evaluation of new 7-aryl or 7-heteroarylamino-2,3-dimethylbenzo[*b*]thiophenes obtained by Buchwald-Hartwig C-N cross-coupling. *Bioorg. Med. Chem.* **2007**, *15*, 1788-1794.

27. Rodriguez, J.G.; Esquivias, J.; Lafuente, A.; Rubio, L. Synthesis of conjugated 2 and 2,5-(ethenyl) and (ethynyl)phenylethynyl thiophenes: fluorescence properties. *Tetrahedron* **2006**, *62*, 3112-3122.

28. Raju, S.; Kumar, P.R.; Mukkanti, K.; Annamalai, P.; Pal, M. Facile synthesis of substituted thiophenes via Pd/C-mediated sonogashira coupling in water. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 6185-6189.

29. Shams, H.Z.; Elkholy, Y.M.; Azzam, R,A.; Mohareb, R.M. Synthetic potentialities of thiophene systems in heterocyclic synthesis: Anovel synthesis of thieno[2,3-*b*]pyridine derivatives. *Phosph. Sulf. Silicon* **1999**, *155*, 215-233.

30. Shams, H.Z.; Mohareb, R.M.; Helal, M.H.; Mahmoud, A.E. Synthesis, structure elucidation, and biological evaluation of some fused and/or pendant thiophene, pyrazole, imidazole, thiazole, triazole, triazine, and coumarin systems based on cyanoacetic 2-[(benzoylamino)thioxomethyl]-hydrazide. *Phosph. Sulf. Silicon* **2007**, *182*, 237-263.

31. Sherif, S.M.; Mohareb, R.M.; Shams, H.Z.; Gaber, H.M. A convenient synthesis of polyfunctionally substituted benzo[*b*]thiophen-2-yl-pyrimidine,-pyrazole,-isoxazole and-pyridazine derivatives. *J. Chem. Res.* **1995**, *(S)*, 434-435; *(M)* 2658-2674.

32. Gewald, K.; Schindler, R. Cyclisierungen mit Cyanthioacetamid in Gegenwart von Schwefel. *J. Prakt. Chem.* **1990**, *332*, 223-228.

33. Mohareb, R.M.; Aziz, S.I.; Sayed, N.I.A.; Shams, H.Z. Reactions of benzoyl isothiocyanate with active methylene reagents: A novel synthesis of thiophene, thiazoline and thieno[2,3-*d*]pyrimidine derivatives. *J. Chin. Chem. Soc.* **1992**, *39*, 181-187.

34. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines. *J. NCI. J. Natl. Cancer Inst.* **1991**, *83*, 757-766.

35. Li, L.; Yu, F.-H. Transcriptional specificities of adriamycin. *Biochem. Mol. Biol. Int.* **1993**, *31*, 879-887.

Sample Availability: Samples of the compounds **2-17b** are available from the authors.